Anastasia Tsakmaklis

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Encapsulated faecal microbiota transfer to target immune activation in patients with cirrhosis and ascites (TransImmune): protocol for a randomised, double-blind, Phase IIa, placebo-controlled trial.

Encapsulated faecal microbiota transfer to target immune activation in patients with cirrhosis and ascites (TransImmune): protocol for a randomised, double-blind, Phase IIa, placebo-controlled trial.

Journal: BMJ open
Published: August 12, 2026

Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial.

Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial.

Journal: Nature communications
Published: February 26, 2026

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Journal: BMJ open
Published: September 10, 2025

The Gut Microbiome in Autosomal Dominant Polycystic Kidney Disease: A Cross-Sectional Study.

The Gut Microbiome in Autosomal Dominant Polycystic Kidney Disease: A Cross-Sectional Study.

Journal: Kidney360
Published: November 05, 2024

In vitro validation concept for lyophilized fecal microbiota products with a focus on bacterial viability.

In vitro validation concept for lyophilized fecal microbiota products with a focus on bacterial viability.

Journal: World journal of microbiology & biotechnology
Published: October 14, 2024

TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.

TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.

Journal: BMC cancer
Published: July 29, 2023

Torque teno virus-DNA load as individual cytomegalovirus risk assessment parameter upon allogeneic hematopoietic stem cell transplantation.

Torque teno virus-DNA load as individual cytomegalovirus risk assessment parameter upon allogeneic hematopoietic stem cell transplantation.

Journal: European journal of haematology
Published: June 07, 2023

Is Autologous Fecal Microbiota Transfer after Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients Rational and Feasible? Data from a Feasibility Test.

Is Autologous Fecal Microbiota Transfer after Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients Rational and Feasible? Data from a Feasibility Test.

Journal: Nutrients
Published: February 15, 2023

The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy.

The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy.

Journal: European journal of neurology
Published: October 22, 2022

Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study.

Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study.

Journal: PloS one
Published: April 08, 2021

Biomarkers of human gut microbiota diversity and dysbiosis.

Biomarkers of human gut microbiota diversity and dysbiosis.

Journal: Biomarkers in medicine
Published: January 14, 2021

Intestinal microbiota-predictor of mortality after stem cell transplantation

Intestinal microbiota-predictor of mortality after stem cell transplantation

Journal: Der Internist
Published: June 07, 2020
Showing 1-12 of 17

Last Updated: 09/26/2026